Literature DB >> 32647946

Characteristics and outcomes of Behçet's syndrome patients with Coronavirus Disease 2019: a case series of 10 patients.

Berna Yurttaş1, Mert Oztas1, Ali Tunc2, İlker İnanç Balkan3, Omer Fehmi Tabak3, Vedat Hamuryudan1, Emire Seyahi4.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32647946      PMCID： PMC7344029          DOI： 10.1007/s11739-020-02427-8

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  16 in total

1.  Anticoagulant interventions in hospitalized patients with COVID-19: A scoping review of randomized controlled trials and call for international collaboration.

Authors:  Tobias Tritschler; Marie-Eve Mathieu; Leslie Skeith; Marc Rodger; Saskia Middeldorp; Timothy Brighton; Per Morten Sandset; Susan R Kahn; Derek C Angus; Marc Blondon; Marc J Bonten; Marco Cattaneo; Mary Cushman; Lennie P G Derde; Maria T DeSancho; Jean-Luc Diehl; Ewan Goligher; Bernd Jilma; Peter Jüni; Patrick R Lawler; Marco Marietta; John C Marshall; Colin McArthur; Carlos Henrique Miranda; Tristan Mirault; Nuccia Morici; Usha Perepu; Christian Schörgenhofer; Michelle Sholzberg; Alex C Spyropoulos; Steve A Webb; Ryan Zarychanski; Stéphane Zuily; Grégoire Le Gal
Journal:  J Thromb Haemost       Date:  2020-10-01       Impact factor: 5.824

Review 2.  Behçet syndrome: a contemporary view.

Authors:  Hasan Yazici; Emire Seyahi; Gulen Hatemi; Yusuf Yazici
Journal:  Nat Rev Rheumatol       Date:  2018-01-03       Impact factor: 20.543

Review 3.  Phenotypes in Behçet's syndrome.

Authors:  Emire Seyahi
Journal:  Intern Emerg Med       Date:  2019-02-11       Impact factor: 3.397

Review 4.  Update on the treatment of Behçet's syndrome.

Authors:  Sinem Nihal Esatoglu; Gulen Hatemi
Journal:  Intern Emerg Med       Date:  2019-01-25       Impact factor: 3.397

5.  Facial Masking for Covid-19. Reply.

Authors:  Monica Gandhi; George W Rutherford
Journal:  N Engl J Med       Date:  2020-10-23       Impact factor: 91.245

6.  Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs.

Authors:  Xabier Michelena; Helena Borrell; Mireia López-Corbeto; María López-Lasanta; Estefanía Moreno; María Pascual-Pastor; Alba Erra; Mayte Serrat; Esther Espartal; Susana Antón; Gustavo Adolfo Añez; Raquel Caparrós-Ruiz; Andrea Pluma; Ernesto Trallero-Araguás; Mireia Barceló-Bru; Miriam Almirall; Juan José De Agustín; Jordi Lladós; Antonio Julià; Sara Marsal
Journal:  Semin Arthritis Rheum       Date:  2020-05-16       Impact factor: 5.532

7.  Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy.

Authors:  Corrado Lodigiani; Giacomo Iapichino; Luca Carenzo; Maurizio Cecconi; Paola Ferrazzi; Tim Sebastian; Nils Kucher; Jan-Dirk Studt; Clara Sacco; Alexia Bertuzzi; Maria Teresa Sandri; Stefano Barco
Journal:  Thromb Res       Date:  2020-04-23       Impact factor: 3.944

8.  More on clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism.

Authors:  L F van Dam; L J M Kroft; L I van der Wal; S C Cannegieter; J Eikenboom; E de Jonge; M V Huisman; F A Klok
Journal:  Thromb Res       Date:  2020-10-09       Impact factor: 3.944

Review 9.  SARS-CoV-2 infection among patients with systemic autoimmune diseases.

Authors:  Giacomo Emmi; Alessandra Bettiol; Irene Mattioli; Elena Silvestri; Gerardo Di Scala; Maria Letizia Urban; Augusto Vaglio; Domenico Prisco
Journal:  Autoimmun Rev       Date:  2020-05-05       Impact factor: 9.754

10.  COVID-19: what the clinician should know about post-mortem findings.

Authors:  Danny Jonigk; Bruno Märkl; Julie Helms
Journal:  Intensive Care Med       Date:  2020-11-03       Impact factor: 17.440
View more
  8 in total

1.  Adamantiades-Behçet's disease (Behçet's disease) and COVID-19.

Authors:  C C Zouboulis; J A M van Laar; M Schirmer; G Emmi; F Fortune; A Gül; Y Kirino; E-S Lee; P P Sfikakis; F Shahram; G R Wallace
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-05-13       Impact factor: 9.228

2.  The course of COVID-19 in patients with Behçet's disease.

Authors:  Ayse Unal Enginar; Mustafa Gundogdu
Journal:  Reumatologia       Date:  2022-01-12

3.  COVID-19 among patients with Behçet syndrome in the United States.

Authors:  Haig Pakhchanian; Rahul Raiker; Sinan Kardeş
Journal:  Clin Rheumatol       Date:  2021-09-25       Impact factor: 3.650

4.  The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Behçet's syndrome.

Authors:  Guzin Ozcifci; Tahacan Aydin; Zeynep Atli; Ilker Inanc Balkan; Fehmi Tabak; Mert Oztas; Yesim Ozguler; Serdal Ugurlu; Gulen Hatemi; Melike Melikoglu; Izzet Fresko; Vedat Hamuryudan; Emire Seyahi
Journal:  Rheumatol Int       Date:  2021-11-25       Impact factor: 3.580

5.  Coronavirus disease 2019 in patients with Behcet's disease: a report of 59 cases in Iran.

Authors:  Farhad Shahram; Kamal Esalatmanesh; Alireza Khabbazi; Zahra Rezaieyazdi; Zahra Mirfeizi; Alireza Sadeghi; Mohsen Soroosh; Hoda Kavosi; Majid Alikhani; Shayan Mostafaei
Journal:  Clin Rheumatol       Date:  2021-11-29       Impact factor: 3.650

Review 6.  COVID-19 Vasculitis and vasculopathy-Distinct immunopathology emerging from the close juxtaposition of Type II Pneumocytes and Pulmonary Endothelial Cells.

Authors:  Sami Giryes; Nicola Luigi Bragazzi; Charles Bridgewood; Gabriele De Marco; Dennis McGonagle
Journal:  Semin Immunopathol       Date:  2022-04-12       Impact factor: 11.759

7.  Clinical course of Covid-19 in a cohort of patients with Behçet disease.

Authors:  María Correa-Rodríguez; José-Luis Callejas-Rubio; Blanca Rueda-Medina; Raquel Ríos-Fernández; Javier de la Hera-Fernández; Norberto Ortego-Centeno
Journal:  Med Clin (Engl Ed)       Date:  2022-09-19

8.  Ocular Behçet disease and COVID-19.

Authors:  Massimo Accorinti; Priscilla Manni; Lorenzo Sampalmieri; Maria Carmela Saturno
Journal:  Eur J Ophthalmol       Date:  2022-01-21       Impact factor: 2.597
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.